From the PFE thread reference a meeting of some sort
Vivus' MUSE One company that suffered at the AUA meeting was Vivus, which has developed an intraurethral formulation of an established treatment for erectile dysfunction, alprostadil, and is already marketing it along with partner Astra. Favorable data was presented on the long-term safety of the product, called MUSE, but most attention centered on a study conducted by researchers at the Presbyterian Hospital in Dallas, USA, which found that only 27% of patients achieved rigidity sufficient for intercourse with the product. Clinical trials conducted in support of its approval had found a 66% success rate.
The study, presented by urologist Pat Fulgham, also found a 41% rate of penile pain and burning in MUSE patients, and just 18% of the 115 men in the study chose to renew their prescriptions.
Vivus shares dropped on the back of media articles pointing to these " disappointing" results, although they bounced back after the company put out a statement noting that many of the patients in the trial had not received the drug at the approved recommended doses. Nevertheless, latest sales figures for the product from IMS America, according to the Wall Street Journal, have suggested that turnover of the product is declining in the face of competition from Viagra.
|
